Radiology Doctors in Rutland, VT Accepting Medicare

8 Radiology doctors found. Showing 1 - 8

Dr. James N Rademacher, M.D. Radiology - Diagnostic Radiology Medicare: Not Enrolled in Medicare Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-775-7111

Dr. Jed Alan Hummel, M.D. Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-3650    Fax: 802-747-1754

Daniel Mitchell, M.D. Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-3650

Jason Mark Beckta, M.D., PH.D. Radiology - Radiation Oncology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-1831

Dr. Trent W Shelton, D.O. Radiology - Vascular & Interventional Radiology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-3650    Fax: 802-747-1754

Andrew Boyer, MD Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-3650

Dr. Richard Dana Lovett, M.D. Radiology - Radiation Oncology Medicare: Accepting Medicare Assignments Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-1831    Fax: 802-747-1826

Roshan Sivagnanam, M.D. Radiology - Diagnostic Radiology Medicare: Medicare Enrolled Practice Location: 160 Allen St, Rutland, VT 05701 Phone: 802-747-3650

News Archive

YouGov survey reveals risks of DVT during long-haul flights

Almost a quarter of UK adults will fly long-haul (over four hours) on holiday or business this year, but are perhaps unaware that one in 25 will suffer an asymptomatic deep vein thrombosis (DVT).

Psychological factors are linked to incorrect fall risk perception in dementia patients

Dementia is associated with an impaired self-perception with potentially harmful consequences for health status and clinical risk classification in this patient group with an extraordinary high risk of falling.

FDA grants five-year New Chemical Entity exclusivity to VYVANSE

Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.

GSK announces new initiatives for addressing healthcare challenges in the world's poorest countries

Andrew Witty, Chief Executive of GlaxoSmithKline, today announced a series of new initiatives targeted at further transforming the company's approach to diseases that disproportionately affect the world's poorest countries. His announcements build on commitments made in 2009 to work in partnership, expand access to medicines and encourage new research into neglected tropical diseases.

Read more Medical News

› Verified 8 days ago